The purpose of this study is to determine the safety and efficacy of DN-101 (calcitriol) in patients with myelodysplastic syndrome who are dependent on repeat blood transfusions.

Condition	Treatment or Intervention	Phase
Myelodysplastic Syndrome	Drug: DN-101 (calcitriol)	Phase II

Further Study Details: 

Expected Total Enrollment:  46

DN-101 is an experimental drug that has not been approved by the Food and Drug Administration (FDA). It is a newly formulated pill that contains high amounts of calcitriol, a naturally occurring hormone and the biologically active form of vitamin D. The natural vitamin D found in dairy products or in typical vitamin pills, must be chemically changed by the liver and kidney into calcitriol before it is biologically active. The body normally uses small amounts of calcitriol to regulate its blood calcium levels. However, for any possible therapeutic effect, MDS patients require much higher levels of calcitriol than the body can produce from dietary vitamin D. DN-101 provides MDS patients with high doses of calcitriol in a pill form.

Laboratory studies have demonstrated evidence supporting the use of calcitriol in MDS. High dose calcitriol slows the growth of leukemic cells (cancerous cells) and increases the growth of normal bone marrow cells. Some patients with MDS may have low levels of calcitriol in their bone marrow.

Clinical study results in patients with MDS have been mixed– some positive and some negative results. Elevated calcium in the blood occurred frequently and prevented the use of higher, more potentially therapeutic doses.

Novacea tested a new formulation of calcitriol, DN-101, in a Phase 1 study. In that study the maximum tolerated dose of DN-101 that did not cause high blood calcium levels when given weekly for several months was determined. That dose is within the range that is potentially therapeutic for MDS patients and will be used in this MDS study.

The purposes of this study are to determine if HDPA DN-101 treatment:

• increases the number of red blood cells, white blood cells, and platelets in the blood
• reduces the number of blood transfusions
• reduces the number of serious infections requiring antibiotics
• reduces the number of serious bleeding events
• improves fatigue

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

• Diagnosis of low or intermediate-1 risk MDS
• Dependent on monthly blood transfusions
• No cancer within the last 5 years (cured skin cancer is allowed)
• No heart attack or stroke within the last 6 months
• No kidney stones within the last 5 years

Alabama
      Clinical Research Consultants, Inc., Hoover,  Alabama,  35216,  United States
California
      University of California, San Francisco, San Francisco,  California,  94143,  United States
Florida
      James A. Haley Veterans Hospital, Tampa,  Florida,  33612,  United States
Illinois
      Rush Cancer Institute MDS Center, Chicago,  Illinois,  60612,  United States
New York
      Roswell Park Cancer Institute, Buffalo,  New York,  14263,  United States
Ohio
      The Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland,  Ohio,  44195,  United States
Oregon
      Oregon Health Sciences University, Portland,  Oregon,  97201,  United States
Tennessee
      Boston Baskin Cancer Group, Memphis,  Tennessee,  38104,  United States
Texas
      University of Texas - MD Anderson Cancer Center, Houston,  Texas,  77030,  United States
Washington
      Fred Hutchinson Cancer Research Center, Seattle,  Washington,  98109,  United States

Study ID Numbers:  DN101-003
Record last reviewed:  February 2005
Last Updated:  February 4, 2005
Record first received:  March 26, 2003
ClinicalTrials.gov Identifier:  NCT00057031
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08